Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
5 Destinations Where Airfare Is Dropping The Most For Spring 2026, Per Dollar Flight Club Analysis - 2Comet Lemmon and Milky Way spotted over Hawaii | Space photo of the day for Dec. 12, 2025
- 3The Best Internet based Courses for Expertise Improvement
- 4Artemis II shares new lunar images while more than halfway to the moon
- 5Discovering a true sense of harmony: Contemplation and Care Practices
- Remote Headphones: Upgrade Your Sound Insight
- IDF destroys Hezbollah rocket launcher used in large rocket salvo towards Haifa, Galilee
- Remain Fit and Sound with These Exercise Fundamentals
- New method spots signs of Earth's primordial life in ancient rocks
- Tributes pour in for MIT professor Nuno Loureiro amid unresolved shooting case
- From Lounge chair to Money: Online Positions That Will Change Your Profession
- Six Flags Opens the Tallest, Fastest and Longest Roller Coaster in the World
- The Most Vital Crossroads in Olympic History
- Huge solar flare no threat to Artemis 2 astronaut launch to the moon, NASA says
